← Back to Screener
CollPlant Biotechnologies Ltd Ordinary Shares (CLGN)
Price$0.37
Favorite Metrics
Price vs S&P 500 (26W)-92.52%
Price vs S&P 500 (4W)-51.44%
Market Capitalization$5.15M
All Metrics
Book Value / Share (Quarterly)$0.73
P/TBV (Annual)3.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-67.95%
Cash Flow / Share (Quarterly)$-0.78
Price vs S&P 500 (YTD)-78.64%
Gross Margin (TTM)63.03%
Net Profit Margin (TTM)-491.31%
EPS (TTM)$-1.02
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-1.02
Revenue Growth (5Y)-25.99%
EPS (Annual)$-1.45
ROI (Annual)-123.35%
Gross Margin (Annual)-160.00%
Net Profit Margin (5Y Avg)-1804.97%
Cash / Share (Quarterly)$0.67
Revenue Growth QoQ (YoY)1825.00%
ROA (Last FY)-88.77%
Revenue Growth TTM (YoY)280.77%
EBITD / Share (TTM)$-0.96
ROE (5Y Avg)-65.77%
Operating Margin (TTM)-497.25%
Cash Flow / Share (Annual)$-1.27
P/B Ratio0.55x
P/B Ratio (Quarterly)3.69x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-1.37x
Net Interest Coverage (TTM)-40.21x
ROA (TTM)-72.12%
EPS Incl Extra (Annual)$-1.45
Current Ratio (Annual)4.44x
Quick Ratio (Quarterly)3.45x
3-Month Avg Trading Volume0.09M
52-Week Price Return-85.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.72
P/S Ratio (Annual)9.99x
Asset Turnover (Annual)0.03x
52-Week High$4.98
Operating Margin (5Y Avg)-1841.80%
EPS Excl Extra (Annual)$-1.45
CapEx CAGR (5Y)-20.17%
26-Week Price Return-83.77%
Quick Ratio (Annual)4.29x
13-Week Price Return-78.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.66x
Enterprise Value$-3.401
Revenue / Share Growth (5Y)-37.31%
Asset Turnover (TTM)0.15x
Book Value / Share Growth (5Y)10.26%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.32x
Pretax Margin (Annual)-3225.05%
Cash / Share (Annual)$1.04
3-Month Return Std Dev159.83%
Gross Margin (5Y Avg)27.41%
Net Income / Employee (TTM)$-0
ROE (Last FY)-123.35%
Net Interest Coverage (Annual)-18.80x
EPS Basic Excl Extra (Annual)$-1.45
Receivables Turnover (TTM)309.38x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.02
Receivables Turnover (Annual)6.87x
ROI (TTM)-102.03%
P/S Ratio (TTM)2.08x
Pretax Margin (5Y Avg)-1804.97%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$1.16
Price vs S&P 500 (52W)-120.34%
Year-to-Date Return-74.50%
5-Day Price Return10.87%
EPS Normalized (Annual)$-1.45
ROA (5Y Avg)-41.38%
Net Profit Margin (Annual)-3225.05%
Month-to-Date Return-33.40%
Cash Flow / Share (TTM)$-0.50
EBITD / Share (Annual)$-1.42
Operating Margin (Annual)-3349.71%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-65.77%
EPS Basic Excl Extra (TTM)$-1.02
P/TBV (Quarterly)3.73x
P/B Ratio (Annual)3.06x
Inventory Turnover (TTM)1.84x
Pretax Margin (TTM)-491.31%
Book Value / Share (Annual)$1.18
Price vs S&P 500 (13W)-81.49%
Beta0.67x
P/FCF (Annual)5.66x
Revenue / Share (TTM)$0.19
ROE (TTM)-102.03%
52-Week Low$0.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.00
4.00
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
CLGNCollPlant Biotechnologies Ltd Ordinary Shares | 2.08x | -25.99% | 63.03% | -497.25% | $0.37 |
ISRGIntuitive Surgical Inc. | 16.54x | 18.22% | 66.00% | 29.27% | $465.60 |
EWEdwards Lifesciences Corp | 7.77x | 6.70% | 78.01% | 18.41% | $81.44 |
STESTERIS plc | 3.81x | 12.49% | 44.11% | 17.03% | $226.41 |
ZBHZimmer Biomet Holdings, Inc. | 2.31x | 3.22% | 69.71% | 13.34% | $95.48 |
ALGNAlign Technology Inc | 3.41x | 10.30% | 68.27% | 13.53% | $191.66 |
SNNSmith & Nephew plc | 2.37x | 6.21% | 68.01% | 12.88% | $34.21 |
MSAMine Safety Incorporated | 3.60x | 6.82% | 46.46% | 19.83% | $173.50 |
ESTAEstablishment Labs Holdings Inc. | 9.30x | 20.04% | 69.32% | -18.48% | $66.93 |
ENOVEnovis Corporation | 0.68x | -6.05% | 58.16% | -50.09% | $26.27 |
CDRECadre Holdings, Inc. | 2.19x | 8.57% | 42.54% | 11.04% | $30.51 |
About
CollPlant Biotechnologies develops regenerative and aesthetic medicine solutions using its proprietary plant-based rhCollagen technology for 3D bioprinting and tissue engineering applications. The company generates revenue through BioInk product sales, rhCollagen therapeutics for aesthetics and medical indications, and strategic partnerships. Its primary markets span the United States, Europe, Canada, and Israel, targeting opportunities in tissue repair, organ manufacturing, and medical aesthetics.